CNTB vs. PASG, CKPT, SLNO, LVTX, LPTX, QNCX, BIOR, UBX, ACHL, and ALGS
Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Passage Bio (PASG), Checkpoint Therapeutics (CKPT), Soleno Therapeutics (SLNO), LAVA Therapeutics (LVTX), Leap Therapeutics (LPTX), Quince Therapeutics (QNCX), Biora Therapeutics (BIOR), Unity Biotechnology (UBX), Achilles Therapeutics (ACHL), and Aligos Therapeutics (ALGS). These companies are all part of the "medical" sector.
Connect Biopharma vs.
Passage Bio (NASDAQ:PASG) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
Passage Bio's return on equity of 0.00% beat Connect Biopharma's return on equity.
61.6% of Passage Bio shares are held by institutional investors. Comparatively, 18.8% of Connect Biopharma shares are held by institutional investors. 12.4% of Passage Bio shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Passage Bio has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Connect Biopharma has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500.
Passage Bio received 31 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 66.67% of users gave Connect Biopharma an outperform vote while only 65.22% of users gave Passage Bio an outperform vote.
Passage Bio presently has a consensus target price of $8.40, suggesting a potential upside of 1,144.26%. Connect Biopharma has a consensus target price of $6.00, suggesting a potential upside of 724.18%. Given Connect Biopharma's higher possible upside, analysts clearly believe Passage Bio is more favorable than Connect Biopharma.
In the previous week, Connect Biopharma had 2 more articles in the media than Passage Bio. MarketBeat recorded 2 mentions for Connect Biopharma and 0 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.75 beat Connect Biopharma's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.
Summary
Connect Biopharma beats Passage Bio on 7 of the 12 factors compared between the two stocks.
Get Connect Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Connect Biopharma Competitors List
Related Companies and Tools